On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma
The main research objective is to evaluate the safety, tolerability, and pharmacokinetic characteristics of UTAA09 cell preparation in the treatment of relapsed/refractory B-cell non Hodgkin's lymphoma patients. The secondary research objective is to explore the clinical efficacy of UTAA09 injection after administration and to explore the content of CD19 positive B cells in peripheral blood after UTAA09 injection administration.
Recurrent or Refractory B-cell Non Hodgkin's Lymphoma
BIOLOGICAL: UTAA09 injection
The incidence of dose limiting toxicity (DLT ), The incidence, severity, and types of dose limiting toxicity, 28 days after infusion|The incidence of TEAEs, The incidence, severity, and types of adverse events that occur during treatment, 28 days after infusion
ORR, Evaluate the overall response rate based on the efficacy criteria of Lugano 2014, 24 months after infusion|PFS, Evaluate the progression free survival based on the efficacy criteria of Lugano 2014, 24 months after infusion|OS, Evaluate the overall survival based on the efficacy criteria of Lugano 2014, 24 months after infusion
Single dose, single arm trial, exploring the initial 28 day safety and efficacy of the investigational drug.